1. Home
  2. EXAI vs ABCL Comparison

EXAI vs ABCL Comparison

Compare EXAI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAI
  • ABCL
  • Stock Information
  • Founded
  • EXAI 2012
  • ABCL 2012
  • Country
  • EXAI United Kingdom
  • ABCL Canada
  • Employees
  • EXAI N/A
  • ABCL N/A
  • Industry
  • EXAI Biotechnology: Biological Products (No Diagnostic Substances)
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXAI Health Care
  • ABCL Health Care
  • Exchange
  • EXAI Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • EXAI 638.2M
  • ABCL 719.0M
  • IPO Year
  • EXAI 2021
  • ABCL 2020
  • Fundamental
  • Price
  • EXAI $5.06
  • ABCL $2.68
  • Analyst Decision
  • EXAI Hold
  • ABCL Buy
  • Analyst Count
  • EXAI 4
  • ABCL 3
  • Target Price
  • EXAI $7.00
  • ABCL $11.00
  • AVG Volume (30 Days)
  • EXAI 692.8K
  • ABCL 1.6M
  • Earning Date
  • EXAI 11-07-2024
  • ABCL 11-04-2024
  • Dividend Yield
  • EXAI N/A
  • ABCL N/A
  • EPS Growth
  • EXAI N/A
  • ABCL N/A
  • EPS
  • EXAI N/A
  • ABCL N/A
  • Revenue
  • EXAI $26,566,153.00
  • ABCL $33,054,000.00
  • Revenue This Year
  • EXAI $156.33
  • ABCL N/A
  • Revenue Next Year
  • EXAI N/A
  • ABCL $44.70
  • P/E Ratio
  • EXAI N/A
  • ABCL N/A
  • Revenue Growth
  • EXAI N/A
  • ABCL N/A
  • 52 Week Low
  • EXAI $3.80
  • ABCL $2.34
  • 52 Week High
  • EXAI $7.91
  • ABCL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • EXAI 52.39
  • ABCL 55.91
  • Support Level
  • EXAI $4.54
  • ABCL $2.43
  • Resistance Level
  • EXAI $5.13
  • ABCL $2.62
  • Average True Range (ATR)
  • EXAI 0.25
  • ABCL 0.11
  • MACD
  • EXAI 0.06
  • ABCL 0.02
  • Stochastic Oscillator
  • EXAI 63.16
  • ABCL 94.74

About EXAI Exscientia Plc

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: